APRE - CIK 0001781983
The table below shows Aprea Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.89M | -$13.56M | -$12.18M | -$25.01M | -$37.69M | -$41.80M |
| Capital expenditure | - | $15.48K | $93.09K | - | - | $25.71K |
| Investing cash flow | - | -$15.48K | -$93.09K | - | - | -$25.71K |
| Dividends paid | - | - | - | - | - |
Aprea Therapeutics, Inc. reported operating cash flow of -$12.89M for fiscal year 2025. That is up 4.9% from -$13.56M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$14.00M (FY 2017) to -$12.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $4.64M | $14.82M | $5.14M | $682.97K | $1.75M | $150.95K |